Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J. Weir MR, et al. Among authors: ashton v. Curr Med Res Opin. 2017 Oct;33(10):1891-1900. doi: 10.1080/03007995.2017.1339674. Epub 2017 Jul 11. Curr Med Res Opin. 2017. PMID: 28590785
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
Coleman CI, Fermann GJ, Weeda ER, Wells PS, Ashton V, Crivera C, Bunz TJ, Wildgoose P, Schein JR, Peacock WF. Coleman CI, et al. Among authors: ashton v. Clin Appl Thromb Hemost. 2017 Oct;23(7):830-837. doi: 10.1177/1076029616661415. Epub 2016 Aug 1. Clin Appl Thromb Hemost. 2017. PMID: 27481875 Free article.
Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.
Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED. Coleman C, et al. Among authors: ashton v. Curr Med Res Opin. 2017 Jun;33(6):1033-1043. doi: 10.1080/03007995.2017.1297932. Epub 2017 Apr 2. Curr Med Res Opin. 2017. PMID: 28366075
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S. Khorana AA, et al. Among authors: ashton v. Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20. Clin Ther. 2017. PMID: 28645879
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
Kohn CG, Fermann GJ, Peacock WF, Wells PS, Baugh CW, Ashton V, Crivera C, Schein JR, Wildgoose P, Coleman CI. Kohn CG, et al. Among authors: ashton v. Curr Med Res Opin. 2017 Sep;33(9):1697-1703. doi: 10.1080/03007995.2017.1349659. Epub 2017 Jul 17. Curr Med Res Opin. 2017. PMID: 28665208 Review.
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P. Wells PS, et al. Among authors: ashton v. J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16. J Med Econ. 2018. PMID: 29469638 Free article. Clinical Trial.
87 results